|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
24
|
|
pubmed:dateCreated |
1998-12-17
|
|
pubmed:abstractText |
We have previously shown that appropriate modification of the benzocycloheptapyridine tricyclic ring system can provide potent farnesyl protein transferase (FPT) inhibitors with good cellular activity. Our laboratories have also established that incorporation of either pyridinylacetyl N-oxide or 4-N-carboxamidopiperidinylacetyl moieties results in pharmacokinetically stable inhibitors that are orally efficacious in nude mice. We now demonstrate that further elaboration of the tricyclic ring system by introducing a bromine atom at the 7- or the 10-position of the 3-bromo-8-chlorotricyclic ring system provides compounds that have superior potency and selectivity in FPT inhibition. These compounds have good serum levels and half-lives when given orally to rodents and primates. In vitro and in vivo evaluation of a panel of these inhibitors has led to identification of 15 (SCH 66336) as a highly potent (IC50 = 1.9 nM) antitumor agent that is currently undergoing human clinical trials.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0022-2623
|
|
pubmed:author |
pubmed-author:AfonsoAA,
pubmed-author:AlvarezC SCS,
pubmed-author:BishopW RWR,
pubmed-author:ConnollyMM,
pubmed-author:CooperA BAB,
pubmed-author:DesaiJJ,
pubmed-author:DeskusJJ,
pubmed-author:GangulyA KAK,
pubmed-author:KellyJJ,
pubmed-author:KirschmeierPP,
pubmed-author:LimY LYL,
pubmed-author:MallamsA KAK,
pubmed-author:NjorogeF GFG,
pubmed-author:PattonRR,
pubmed-author:PinteFF,
pubmed-author:RaneD FDF,
pubmed-author:RemiszewskiSS,
pubmed-author:RossmanR RRR,
pubmed-author:TaverasA GAG,
pubmed-author:VibulbhanBB,
pubmed-author:WangJJ,
pubmed-author:WangLL,
pubmed-author:WolinRR,
pubmed-author:WongJJ,
pubmed-author:del RosarioJJ
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
19
|
|
pubmed:volume |
41
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
4890-902
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9822558-Alkyl and Aryl Transferases,
pubmed-meshheading:9822558-Animals,
pubmed-meshheading:9822558-Antineoplastic Agents,
pubmed-meshheading:9822558-COS Cells,
pubmed-meshheading:9822558-Drug Screening Assays, Antitumor,
pubmed-meshheading:9822558-Enzyme Inhibitors,
pubmed-meshheading:9822558-Humans,
pubmed-meshheading:9822558-Macaca fascicularis,
pubmed-meshheading:9822558-Mice,
pubmed-meshheading:9822558-Mice, Nude,
pubmed-meshheading:9822558-Piperidines,
pubmed-meshheading:9822558-Protein Prenylation,
pubmed-meshheading:9822558-Pyridines,
pubmed-meshheading:9822558-Stereoisomerism,
pubmed-meshheading:9822558-Structure-Activity Relationship,
pubmed-meshheading:9822558-Tumor Cells, Cultured
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
(+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamid e (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent.
|
|
pubmed:affiliation |
Departments of Chemistry and Tumor Biology, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, USA.
|
|
pubmed:publicationType |
Journal Article
|
